Today, the U.S. Food and Drug Administration (FDA) announced that they will encourage use of medication-assisted treatments (MAT).
WASHINGTON, DC – Today, the U.S. Food and Drug Administration (FDA) announced that they will encourage use of medication-assisted treatments (MAT), such as methadone and buprenorphine, among people treating their opioid use disorders.
Shatterproof Founder and CEO Gary Mendell released the following statement on the announcement:
“The FDA’s move to support MAT is a huge step in the right direction towards effectively addressing the opioid epidemic. Numerous studies show that MAT works, despite what critics say. Shatterproof and our allies have been calling for an evidence-based approach for years, and focusing on MAT is doing just that.
“Commissioner Gottlieb also emphasized the important role insurers play in treating addiction. The Substance Use Disorder Treatment Task Force has convened insurers for the first time to agree on a common set of principles to provide quality addiction treatment. The FDA’s announcement is completely in line with the goals the Task Force is working towards, which we’re looking forward to announcing in the coming weeks.”
About Gary Mendell:
Gary Mendell is the founder and CEO of Shatterproof. He founded Shatterproof to spare others the tragedy his family suffered with the loss of his son Brian to addiction in 2011. Mr. Mendell is an experienced businessman and CEO who founded HEI Hotels & Resorts and is the former president of Starwood Lodging Trust.
Shatterproof is a national nonprofit organization dedicated to reducing the devastation the disease of addiction causes families. Shatterproof works to end the stigma and foster a community of support, providing evidence-based resources to support prevention, treatment and recovery. Shatterproof advocates for changes in policy at the federal and state level and supports the development and implementation of evidence-based solutions for substance use disorders.